Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients.
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Brimonidine/dorzolamide/timolol (Primary) ; Dorzolamide/timolol (Primary) ; Latanoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Acronyms PRO-122
- Sponsors Laboratorios Sophia
- 05 Dec 2023 Status changed from recruiting to discontinued.
- 26 Dec 2022 Planned End Date changed from 30 Apr 2022 to 30 Apr 2023.
- 26 Dec 2022 Planned primary completion date changed from 30 Apr 2022 to 30 Apr 2023.